Sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: Characterization, cellular uptake, cytotoxicity, and biodistribution
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Chang Hyun | - |
dc.contributor.author | Sung, Si Woo | - |
dc.contributor.author | Lee, Eun Seok | - |
dc.contributor.author | Kang, Tae Hoon | - |
dc.contributor.author | Yoon, Ho Yub | - |
dc.contributor.author | Goo, Yoon Tae | - |
dc.contributor.author | Cho, Ha Ra | - |
dc.contributor.author | Kim, Dong Yoon | - |
dc.contributor.author | Kang, Myung Joo | - |
dc.contributor.author | Choi, Yong Seok | - |
dc.contributor.author | Lee, Sangkil | - |
dc.contributor.author | Choi, Young Wook | - |
dc.date.available | 2019-03-08T06:56:01Z | - |
dc.date.issued | 2018-12 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3213 | - |
dc.description.abstract | As a platform for hepsin-specific drug delivery, we previously prepared IPLVVPLRRRRRRRRC peptide (RIPL)-conjugated nanostructured lipid carriers (RIPL-NLCs) composed of Labrafil® M 1944 CS (liquid oil) and Precirol® ATO 5 (solid lipid). In this study, to prevent the recognition by the mononuclear phagocyte system, polyethylene glycol (PEG)-modified RIPL-NLCs (PEG-RIPL-NLCs) were prepared using PEG3000 at different grafting ratios (1, 5, and 10 mole %). All prepared NLCs showed a homogeneous dispersion (130–280 nm), with zeta potentials varying from −18 to 10 mV. Docetaxel (DTX) was successfully encapsulated in NLCs: encapsulation efficiency (93–95%); drug-loading capacity (102–109 µg/mg). PEG-RIPL-NLCs with a grafting ratio of 5% PEG or higher showed significantly reduced protein adsorption and macrophage phagocytosis. The uptake of PEG(5%)-RIPL-NLCs by cancer cell lines was somewhat lower than that of RIPL-NLCs because of the PEG-induced steric hindrance; however, the uptake level of PEG-RIPL-NLCs was still greater than that of plain NLCs. In vivo biodistribution was evaluated after tail vein injection of NLCs to normal mice. Compared to RIPL-NLCs, PEG(5%)-RIPL-NLCs showed lower accumulation in the liver, spleen, and lung. In conclusion, we found that PEG(5%)-RIPL-NLCs could be a promising nanocarrier for selective drug targeting with a high payload of poorly water-soluble drugs. © 2018 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI AG | - |
dc.title | Sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: Characterization, cellular uptake, cytotoxicity, and biodistribution | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/pharmaceutics10040199 | - |
dc.identifier.bibliographicCitation | Pharmaceutics, v.10, no.4 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000455853800037 | - |
dc.identifier.scopusid | 2-s2.0-85055736052 | - |
dc.citation.number | 4 | - |
dc.citation.title | Pharmaceutics | - |
dc.citation.volume | 10 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | nanostructured lipid carrier | - |
dc.subject.keywordAuthor | RIPL peptide | - |
dc.subject.keywordAuthor | cellular uptake | - |
dc.subject.keywordAuthor | steric stabilization | - |
dc.subject.keywordAuthor | cytotoxicity | - |
dc.subject.keywordAuthor | biodistribution | - |
dc.subject.keywordPlus | INTRACELLULAR DRUG-DELIVERY | - |
dc.subject.keywordPlus | PEG | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | LIPOSOMES | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | 10-HYDROXYCAMPTOTHECIN | - |
dc.subject.keywordPlus | NANOCARRIERS | - |
dc.subject.keywordPlus | PEGYLATION | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.